Adam Schoen, Brown Rudnick. “When and How to Talk to Investors and Partners About Your IP”
Investors and strategic partners want to understand your intellectual property so they can assess your chances of advancing your technology in the market. How well-developed does your IP position need to be before you can open discussions? Exactly how much should you reveal? And what do you do when your IP is not patentable? Get the answers Tuesday, September 24 from Adam Schoen, Partner at the law firm Brown Rudnick.
Where & When
Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
5:30 to 6:30 PM, Tuesday, September 24
About the Speaker
Adam Schoen has over a decade of experience representing life science and medical device companies. His practice focuses on implementation of patent strategies to further business objectives and business goals. Adam’s practice is multidisciplinary, encompassing all aspects of patent preparation and prosecution, portfolio development, product clearance, freedom to operate analysis, intellectual property due diligence and licensing. Adam works with public and private companies, investors and academic institutions.
Adam has experience across the life sciences industry, working with therapeutics companies, biologics companies, diagnostic companies and medical device companies. He works with a variety of technologies, such as small molecule therapeutics, biologics (including immunotherapeutics), next generation sequencing technologies, droplet based technologies, diagnostics (including cancer and fertility diagnostics), medical device technology (ophthalmology, cardiology, orthopedics, neurology, spine), medical imaging technology (IVUS and OCT), mass spectrometry, digital health products, near field communication technology and semiconductor technology. He manages patent portfolios of all sizes and develops strategies to maximize and protect intellectual property rights in both the United States and foreign jurisdictions.
Prior to law school, Adam was a scientist of analytical chemistry for ArQule Inc., a combinatorial chemistry and drug discovery company, and a scientist at Millennium Pharmaceuticals, Inc.